Top Markets
Coin of the day
Edesa Biotech, Inc. Edesa Biotech, Inc.

Edesa Biotech, Inc.

EDSA
Rang in aandelen #25796
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Aandeelprijs
$4.80
Laatst gesynchroniseerd: 2026-08-20
Marktkapitalisatie
$46.24M
Verandering (1 dag)
-16.52%
Verandering (1 jaar)
101.68%
Land
CA
Handel Edesa Biotech, Inc. (EDSA)

Categorie

Koersgeschiedenis voor Edesa Biotech, Inc. (EDSA)
Hoogste slotkoers: $5.37 op 2026-08-01

Laagste slotkoers: $602.70 op 2010-06-01
Koersgeschiedenis van Edesa Biotech, Inc. van 2010 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) 189.29%
2025 -16.90%
2024 -58.03%
2023 -48.53%
2022 -77.76%
2021 16.75%
2020 12.06%
2019 -29.49%
2018 -84.76%
2017 -54.18%
2016 -73.20%
2015 -32.44%
2014 -36.36%
2013 592.43%
2012 -41.11%
2011 -62.20%
2010 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$539.14 35.65%
US
$1.04K 56.21%
NL
$119.69 -17.56%
AU
$761.87 8.65%
CH
$130.43 397.46%
US